CWLXF C21 Investments Inc. Annual reports only
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 831609 · Fiscal year ends 03/31
Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY8.3%
TTM net income YoY18.3%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin41.7%
Operating margin7.0%
Net margin-9.9%
FCF margin3.4%
EBITDA margin12.4%
Returns
ROE-12.0%
ROA-5.8%
ROIC (approx.)4.6%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage12.17x
Cash quality & payout
Operating cash flow / net income-0.42x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $32.61M | $30.12M |
| Cost of revenue | $19.01M | $17.56M |
| Gross profit | $13.61M | $12.56M |
| SG&A expense | $11.33M | $11.28M |
| Operating income | $2.28M | $1.28M |
| Interest expense | $187,241 | $293,675 |
| Pretax income | $1.38M | $394,921 |
| Income tax | $4.61M | $4.15M |
| Net income | -$3.24M | -$3.97M |
| EBITDA | $4.06M | $2.99M |
| EPS (basic) | -0.03 | -0.03 |
| EPS (diluted) | -0.03 | -0.03 |
| Weighted avg. shares (diluted) | 118.47M | 120.59M |
| Balance sheet | ||
| Cash & equivalents | $2.23M | $2.63M |
| Receivables | $57,084 | $124,827 |
| Inventory | $4.59M | $4.05M |
| Current assets | $8.31M | $7.50M |
| PP&E, net | $2.30M | $2.67M |
| Goodwill | $28.54M | $28.54M |
| Intangibles | $6.41M | $8.09M |
| Total assets | $54.42M | $57.00M |
| Current liabilities | $6.39M | $7.96M |
| Total liabilities | $28.99M | $28.32M |
| Shareholders' equity | $25.43M | $28.68M |
| Shares outstanding | 117.84M | 118.00M |
| Cash flow statement | ||
| Operating cash flow | $1.36M | $1.37M |
| Capital expenditure | $244,838 | $406,733 |
| Free cash flow | $1.12M | $958,920 |
| Investing cash flow | -$219,838 | -$3.45M |
| Financing cash flow | -$1.54M | $1.67M |
| Depreciation & amortization | $1.78M | $1.71M |
| Stock-based compensation | $236,779 | $849,559 |
| Share buybacks | $103,034 | $276,730 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.